An Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC.

This document provides information about a clinical trial conducted by Guangzhou University of Traditional Chinese Medicine in China. The trial aims to study the effectiveness of Fuquinitinib combined with Tegafur Gimeracil Oteracil in the third-line treatment of patients with advanced metastatic colorectal cancer. The trial is currently in Phase II and is open, single-arm, multicenter, and prospective. The primary outcome measures include progression-free survival, objective response rate, disease control rate, overall survival, and safety and tolerance. The trial is not yet recruiting participants and aims to enroll 52 individuals, with an estimated completion date of February 18, 2027. [Extracted from the article]